Angiotensin-converting-enzyme inhibitors slow renal decline in IgA nephropathy, independent of tubulointerstitial fibrosis at presentation

QJM: An International Journal of Medicine

Volumn 98, Issue 3, 2005, Pages 199-203

  Kanno, Y ^b   Okada, H ^b   Yamaji, Y ^a   Nakazato, Y ^a   Suzuki, H ^b  

^a Saitama Social Insurance Hospital   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TEMOCAPRIL; TRANDOLAPRIL;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE CLEARANCE; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FAILURE; KIDNEY FIBROSIS; MALE; MICROSCOPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINALYSIS;

EID: 14944372083     PISSN: 14602725     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/hci036     Document Type: Article

References (31)

1. Okada H, Strutz F, Danoff TM, et al. Possible mechanisms of renal fibrosis. Contrib Nephrol 1996; 118 147-54.
2. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998; 339:1448-56.
3. Eddy A. Molecular basis of renal fibrosis. Pediatr Nephrol 2000; 15:290-301.
4. Striker G, Schainuck L, Cutler R, et al. Structural-functional correlations in renal disease. 1. The correlations. Hum Pathol 1970; 1:615-30.
5. Risdon R, Sloper J, De Vardener H. Relationship between renal function and histologic changes found in renal-biopsy specimens from patients with persistent glomerulonephritis. Lancet 1968; 2 363-6.
6. Bohle A, Mackensen-Haen S, Von Gise H. Significance of tubulointerstitial changes in the renal cortex for the excretory function and concentration ability of the kidney: A morphometric contribution. Am J Nephrol 1989; 7:421-33.
7. The GISEN Group. Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349:1857-63.
8. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334:939-45.
9. Remuzzi G, Ruggenenti P, Perico N. Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 2002; 136:604-15.
10. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329:1456-62.
11. Cordonnier DJ, Pinel N, Barro C, et al. Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. The Diabiopsies Group. J Am Soc Nephrol 1999; 10:1253-63.
12. Cao Z, Cooper ME. Role of angiotensin II in tubulointerstitial injury. Semin Nephrol 2001; 6:554-62.
13. Jover B, Demeilliers B. Angiotensin II type 1 receptor antagonist versus angiotensin I-converting enzyme inhibitor in experimental renal diseases. Fundam Clin Pharmacol 2000; 14 541-8.
14. Ruiz-Ortega M, Egido J. Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts. Kidney Int 1997; 52:1497-510.
15. Praga M, Gutierrez E, Gonzalez E, et al. Treatment of IgA Nephropathy with ACE Inhibitors: A Randomized and Controlled Trial. J Am Soc Nephrol 2003; 14:1578-83.
16. Park HC, Xu ZG, Choi S, et al. Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy. Nephrol Dial Transplant 2003; 18 1115-21.
17. Kanno Y, Suzuki H, Okada H, et al. Calcium channel blockers versus ACE inhibitors as antihypertensives in polycystic kidney disease. Q J Med 1996; 89:65-70.
18. Velasquez MT, Abraham AA, Kimmel PL, et al. Diabetic glomerulopathy in the SHR/N-corpulent rat: role of dietary carbohydrate in a model of NIDDM. Diabetologia 1995; 38:31-8.
19. Inoue T, Okada H, Kobayashi T, et al. Hepatocyte growth factor counteracts transforming growth factor-beta1, through attenuation of connective tissue growth factor induction, and prevents renal fibrogenesis in 5/6 nephrectomized mice. Faseb J 2003; 17 268-70.
20. Alexopoulos E, Stangou M, Papagianni A, et al. Factors influencing the course and the response to treatment in primary focal segmental glomerulosclerosis. Nephrol Dial Transplant 2000; 15 1348-56.
21. Abbate M, Zoja C, Corna D, et al. In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. J Am Soc Nephrol 1998; 9:1213-24.
22. Lonnemann G, Shapiro L, Engler-Blum G, et al. Cytokines in human renal interstitial fibrosis. I. Interleukin-1 is a paracrine growth factor for cultured fibrosis-derived kidney fibroblasts. Kidney Int 1995; 47:837-44.
23. Lonnemann G, Engler-Blum G, Mueller GA, et al. Cytokines in human renal interstitial fibrosis. II. Intrinsic interleukin (IL)-1 synthesis and IL-1-dependent production of IL-6 and IL-8 by cultured kidney fibroblasts. Kidney Int 1995; 47:845-54.
24. Mueller GA, Rodemann HP. Characterization of human renal fibroblasts in health and disease: I. Immunophenotyping of cultured tubular epithelial cells and fibroblasts derived from kidneys with histologically proven interstitial fibrosis. Am J Kidney Dis 1991; 17:680-3.
25. Rodemann HP, Mueller GA. Characterization of human renal fibroblasts in health and disease: II. In vitro growth, differentiation, and collagen synthesis of fibroblasts from kidneys with interstitial fibrosis. Am J Kidney Dis 1991; 17:684-6.
26. Schuttert JB, Liu MH, Gliem N, et al. Human renal fibroblasts derived from normal and fibrotic kidneys show differences in increase of extracellular matrix synthesis and cell proliferation upon angiotensin II exposure. Pflugers Arch 2003; 446:387-93.
27. Sealey JE, Moon C, Laragh JH, et al. Plasma prorenin in normal, hypertensive, and anephric subjects and its effect on renin measurements. Circ Res 1977; 40:I41-5.
28. Yoshida H, Mitarai T, Kawamura T, et al. Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 1995; 96:2162-9.
29. Schena FP, D'Altri C, Cerullo G, et al. ACE gene polymorphism and IgA nephropathy: an ethnically homogeneous study and a meta-analysis. Kidney Int 2001; 60:732-40.
30. Russo D, Pisani A, Balletta MM, et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999; 33:851-6.
31. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361 117-24.